Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | PRESIDENT AND COO | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Gift · Disposed 11,728 · Balance 0 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Indirectby Trust | 99,720 |
Reported balance
After 2026-05-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-13 · Gift · Acquired 11,728 · Balance 99,720 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2025 Filed Sep 17, 2025 10:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,052 | $403.00 | $826,965.03 |
DisclosureSEC source: 0001104659-25-090543 · tm2526270-1_4seq1.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3,2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $402.73 to $403.51. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of whichthe Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 10:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,470 | $402.06 | $591,034.82 |
DisclosureSEC source: 0001104659-25-090543 · tm2526270-1_4seq1.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,052 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3,2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $401.67 to $402.64. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of whichthe Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 10:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 5,103 | $400.79 | $2,045,226.78 |
DisclosureSEC source: 0001104659-25-090543 · tm2526270-1_4seq1.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,522 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3,2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $400.54 to $401.39. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of whichthe Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 10:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,910 | $400.09 | $1,164,253.75 |
DisclosureSEC source: 0001104659-25-090543 · tm2526270-1_4seq1.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 8,625 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3,2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $399.54 to $400.52. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of whichthe Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 10:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,415 | $399.07 | $564,688.58 |
DisclosureSEC source: 0001104659-25-090543 · tm2526270-1_4seq1.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 11,535 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3,2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $398.54 to $399.53. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of whichthe Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 10:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,380 | $398.02 | $549,268.29 |
DisclosureSEC source: 0001104659-25-090543 · tm2526270-1_4seq1.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 12,950 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3,2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $397.53 to $398.50. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of whichthe Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 10:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 295 | $396.95 | $117,100.99 |
DisclosureSEC source: 0001104659-25-090543 · tm2526270-1_4seq1.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,330 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3,2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $396.44 to $397.34. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of whichthe Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 10:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $135.42 | $1,980,517.50 |
DisclosureSEC source: 0001104659-25-090543 · tm2526270-1_4seq1.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3,2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of whichthe Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,125 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · derivative · entry 21 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 49,000 Underlying: Common Stock · 6,125 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F9 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 11,375 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · derivative · entry 20 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 158,250 Underlying: Common Stock · 11,375 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 6,500 | $400.08 | $2,600,528.45 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 16 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F15 · price: This transaction was executed in multiple trades at prices ranging from $400.00 to $400.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,875 | $393.86 | $1,920,045.08 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 15 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 6,500 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F14 · price: This transaction was executed in multiple trades at prices ranging from $393.73 to $394.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 11,375 | $397.41 | $4,520,572.88 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 14 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 11,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,750 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · derivative · entry 19 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 24,500 Underlying: Common Stock · 1,750 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F9 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,250 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · derivative · entry 18 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 169,625 Underlying: Common Stock · 3,250 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $396.10 | $39,610.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 13 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F9 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 350 | $394.33 | $138,014.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 12 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 100 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $394.03 to $394.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $392.51 | $157,002.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 450 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · price: This transaction was executed in multiple trades at prices ranging from $392.08 to $392.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $391.42 | $156,566.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 850 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $391.06 to $391.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 500 | $390.46 | $195,230.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 1,250 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $389.87 to $390.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,750 | $146.03 | $255,552.50 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 1,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F9 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $396.23 | $79,245.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $396.22 to $396.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 233 | $395.03 | $92,043.06 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 200 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $394.63 to $395.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $394.08 | $118,224.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 433 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $393.53 to $394.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,100 | $392.18 | $431,396.02 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 733 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $391.78 to $392.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,000 | $391.16 | $391,156.30 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 1,833 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $390.76 to $391.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 417 | $389.81 | $162,552.52 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,833 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $389.45 to $390.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,250 | $135.42 | $440,115.00 |
DisclosureSEC source: 0001673232-25-000003 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,875 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · derivative · entry 21 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 55,125 Underlying: Common Stock · 7,875 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 14,625 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · derivative · entry 20 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 172,875 Underlying: Common Stock · 14,625 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 6,125 | $419.63 | $2,570,233.75 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 18 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 95 | $419.61 | $39,862.89 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 17 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 6,125 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F16 · price: This transaction was executed in multiple trades at prices ranging from $418.65 to $419.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F12 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 367 | $417.45 | $153,204.19 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 16 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 6,220 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F15 · price: This transaction was executed in multiple trades at prices ranging from $417.20 to $417.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F12 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $410.35 | $41,035.00 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 15 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 6,587 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $408.28 | $122,482.74 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 14 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 6,687 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F14 · price: This transaction was executed in multiple trades at prices ranging from $408.22 to $408.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F12 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 888 | $407.26 | $361,650.61 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 13 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 6,987 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $407.20 to $407.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F12 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 72 | $419.35 | $30,193.30 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $418.77 to $419.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 328 | $418.03 | $137,114.07 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 72 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $417.74 to $418.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $416.30 | $83,260.72 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 400 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $416.24 to $416.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 32 | $413.39 | $13,228.38 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 600 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $413.35 to $413.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 168 | $412.69 | $69,332.63 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 632 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $412.34 to $413.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,144 | $409.97 | $469,005.45 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 800 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $409.48 to $410.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $408.97 | $286,280.47 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 1,944 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $408.39 to $409.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 500 | $407.34 | $203,668.55 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,644 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $407.20 to $407.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 106 | $405.59 | $42,993.06 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,144 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $405.54 to $406.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 11,375 | $419.63 | $4,773,291.25 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,250 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $135.42 | $1,980,517.50 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| September 01, 2025 Filed Sep 4, 2025 11:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,875 | $146.03 | $1,149,986.25 |
DisclosureSEC source: 0001673232-25-000002 · primarydocument.xml · nonDerivative · entry 12 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 2,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002291 · primarydocument.xml · derivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $323.99 | $32,399.00 |
DisclosureSEC source: 0001562180-25-002291 · primarydocument.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.